Enliven Therapeutics, Inc. $ELVN Shares Purchased by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in Enliven Therapeutics by 61.3%, owning approximately 0.43% of the company worth $4.17 million as of its latest filing.
• Multiple analysts have recently raised their price targets for Enliven Therapeutics, with an average target of $41.20 and ratings predominantly reflecting a "Buy" sentiment.
• Recent insider trading saw CFO Benjamin Hohl and CEO Samuel Kintz sell shares, indicating a 12.38% and 1.11% decrease in their respective ownership positions.

Goldman Sachs Group Inc. increased its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 61.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 211,752 shares of the company's stock after buying an additional 80,506 shares during the period. Goldman Sachs Group Inc. owned about 0.43% of Enliven Therapeutics worth $4,167,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Rhumbline Advisers raised its position in Enliven Therapeutics by 4.9% during the first quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock worth $1,033,000 after acquiring an additional 2,466 shares during the last quarter. Jane Street Group LLC acquired a new position in Enliven Therapeutics during the first quarter worth about $578,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company's stock worth $428,000 after acquiring an additional 1,693 shares during the last quarter. Ally Bridge Group NY LLC raised its position in Enliven Therapeutics by 19.8% during the first quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company's stock worth $3,341,000 after acquiring an additional 28,064 shares during the last quarter. Finally, Tema Etfs LLC acquired a new position in Enliven Therapeutics during the first quarter worth about $465,000. Institutional investors and hedge funds own 95.08% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Robert W. Baird lifted their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, June 16th. HC Wainwright lifted their target price on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Finally, The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They issued a "buy" rating and a $37.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $41.20.

Enliven Therapeutics Trading Down 4.8%

ELVN traded down $0.96 during trading on Friday, hitting $18.96. 2,310,053 shares of the company's stock were exchanged, compared to its average volume of 523,887. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $30.03. The stock has a 50 day moving average price of $20.11 and a 200 day moving average price of $19.67. The firm has a market cap of $1.12 billion, a P/E ratio of -9.48 and a beta of 0.89.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. Analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction on Thursday, July 17th. The shares were sold at an average price of $22.52, for a total value of $281,500.00. Following the completion of the transaction, the chief executive officer directly owned 940,392 shares in the company, valued at approximately $21,177,627.84. This represents a 1.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Anish Patel sold 6,667 shares of the company's stock in a transaction on Monday, September 8th. The shares were sold at an average price of $20.24, for a total transaction of $134,940.08. Following the completion of the transaction, the chief operating officer owned 283,308 shares of the company's stock, valued at $5,734,153.92. This trade represents a 2.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 85,234 shares of company stock valued at $1,756,514 over the last ninety days. 25.90% of the stock is owned by company insiders.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.